Skip to main content
Equibles
SYRE logo

SYRE · Spyre Therapeutics, Inc. · Analyst Estimates

Track SYRE — free

Use SYRE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SYRE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$90.60 +1.89 (+2.13%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”
View the 10-Q filed Aug 4, 2026
Market Cap
$7.81B
Shares
88.17M

Analyst Estimates

Compare analyst forecasts for Spyre Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Only independently verified consensus published through the company's investor-relations sources is available.

Consensus not yet available

Only independently verified consensus published through the company's investor-relations sources is available.

Key facts CIK 1636282 CUSIP 00773J202 13F (30d) 161 filings 160 filers Visit website Investor relations